RT Journal Article
SR Electronic
T1 COVID-19 and heart medications: What’s the connection?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20174367
DO 10.1101/2020.08.24.20174367
A1 Saleknezhad, Nafiseh
A1 Khosravi, Bardia
A1 Anushiravani, Amir
A1 Eslahi, Masoud
A1 Radmard, Amir Reza
A1 Sirusbakht, Azin
A1 Pourabbas, Seyed Mohammad
A1 Abdollahi, Mohammad
A1 Kasaeian, Amir
A1 Sorouri, Majid
A1 Sima, Ali Reza
YR 2020
UL http://medrxiv.org/content/early/2020/08/26/2020.08.24.20174367.abstract
AB Aim To determine association between clinical outcome of COVID-19 and prior usage of cardiovascular and metabolic drugs, including, Aspirin, ACEIs, ARBs, Clopidogrel, metformin, and Statins.Methods Statistical examination of the demographic, clinical, laboratory and imaging features of 353 patients with SARS-CoV-2 disease admitted from February to April 2020.Result Minor discrepancies were observed in the clinical presentations, radiologic involvement and laboratory results across groups of patients under treatment with specific drugs. Aspirin-users had better clinical outcome with lower need of ventilation support, whereas, metformin- users had increased chance of intubation and of mortality.Conclusion Although not being conclusive, our findings suggest the possibility of the effect of previous drug usages on the various presentations and clinical course of COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Tehran University of Medical Sciences. The ethics committee waived the requirement for informed patient consent for this retrospective study subject to the anonymity of patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe shall declare that we are not allowed to disclose publically our data. Individual researchers and research institutes can request to access data by contacting the corresponding author.